ClinicalTrials.gg
CompletedNCT06070506Updated Oct 11, 2023

Heart Failure With Improved Ejection Fraction and Deep Learning

An observational study in Heart Failure and Diagnosis, sponsored by Yihui Kong. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Yihui Kong · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
422
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Enrollment
74th of 130
422 · median 554
Started
2022
with 28 others
Observational
130 of 377
64 open now
Registered
216th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 74th largest by enrollment of the 130 observational ones that give a count, is one of 29 that started in 2022, is one of 130 observational ones, and was the 216th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to design a deep learning-based trained model to assist in HFimpEF diagnosis.

03

Conditions studied

  • Heart Failure
  • Diagnosis

Keywords

  • Heart failure
  • Left ventricular ejection fraction
  • Heart failure with improved ejection fraction
  • Deep learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The participants in the study are HF patients hospitalized in the Department of Cardiology of the First Affiliated Hospital of Harbin Medical University who had no less than two echocardiograms at baseline and during the follow-up period, between January 2014 to December 2022.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. The diagnostic criteria of HF follows the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, having symptoms of dyspnea, fatigue or decreased activity tolerance, having signs of fluid retention (such as pulmonary congestion and peripheral edema), having echocardiogram abnormalities in cardiac structure and/or function, showing elevated natriuretic peptide levels (BNP>35 ng/L or/and N-terminal pro-BNP >125 ng/L).
  3. Have reviewing echocardiography after discharge.

Exclusion criteria

Exclusion Criteria:

  1. Patients with hypertrophic, restrictive, or invasive cardiomyopathy and congenital or rheumatic heart disease.
  2. Patients with heart transplantation during follow-up.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
422 participants (actual)
Patient registry
No

Groups and cohorts

  • HFrEF group

    Heart failure patients with LVEF persistently ≤40%.

  • HFimpEF group

    Heart failure patients with previous LVEF ≤40% and a follow-up LVEF of more than 40%.

06

What researchers measure

Primary outcomes

  1. change of left ventricular ejection fraction

    left ventricular ejection fraction value in millimeters

    Time frame: 3 months

Secondary outcomes

  1. change of clinical predictor of EF improvement

    weight in kilograms, height in meters(weight and height will be combined to report BMI in kg/m\^2)

    Time frame: 3 months

  2. the independent clinical predictor of HFimpEF

    prealbumin in mg/L

    Time frame: 3 months

07

Study locations

1 site
  • Yihui Kong
    Harbin, Heilongjiang 150000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Dec 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Oct 6, 2023
StartActual
Mar 1, 2022
Primary completionActual
Dec 31, 2022
CompletionActual
May 20, 2023
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06070506
Lead sponsor
Yihui Kong
Responsible party
Yihui Kong (Professor, First Affiliated Hospital of Harbin Medical University) — Sponsor-investigator
First posted
Oct 6, 2023
Start date
Mar 1, 2022
Primary completion
Dec 31, 2022
Completion
May 20, 2023
Last update
Oct 11, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion